Mayo Clinic Laboratory and Pathology Research Roundup: October 19

The research roundup provides an overview of the past week’s research from Mayo Clinic Laboratories consultants, including featured abstracts and a complete list of published studies and reviews.

Featured Abstract

Novel Methylated DNA Markers in the Surveillance of Colorectal Cancer Recurrence.

Of the 14 selected MDMs, the concordance between primary and metastatic tissue was considered moderate or higher for 12 MDMs (86%). At a preset specificity of 95% (91-98%), a panel of 13 MDMs in plasma from 97 CRC cases and 200 controls detected stage IV CRC with 100% (80-100%) sensitivity and all stages of CRC with an AUC 0.91 (0.87-0.95), significantly higher than CEA (AUC 0.72 (0.65-0.79)). This panel in plasma from 40 cases, and 60 healthy controls detected recurrent/metastatic CRC with 90% (76-97%) sensitivity with specificity of 90% (79-96%) and an AUC of 0.96 (0.92-1).The panel was positive in 0.30 (0.19-0.43) of 60 patients with no evidence of disease post-operative CRC patients. Via Clinical Cancer Research

Read more.

Published to PubMed This Week

Samantha Rossi

Samantha Rossi is a Digital Marketing Manager at Mayo Clinic Laboratories. She supports marketing strategies for product management and specialty testing. Samantha has worked at Mayo Clinic since 2019.